Amy S. Clark, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-7096
Fax: 215-615-3349
BS (Biology)
Haverford College, 1999.
MD (Medicine)
Milton S. Hershey Penn State College of Medicine, 2006.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2012.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I am a medical oncologist who specializes in breast cancer. I only see breast cancer patients in the outpatient setting, but treat patients will all cancers when working in the hospital.

Description of Research Expertise

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications

Marczyk M, Mrukwa A, Yau C, Wolf D, Chen, YY Balassanian R, Nanda R, Parker B A Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, van't Veer L, Symmans WF, Esserman L, Pusztai L : Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 22: S0923-7534, May 2022.

Martei YM, Clark AS: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment. JAMA Netw Open. 5(4), April 2022.

Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Schulman LN,Mamtani R, Hubbard RA, : Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. J Natl Cancer Inst. 114(4): 571-578, April 2022.

Verbus EA, Rossi AJ, Clark AS, Taunk NK, Nayak A, Hernandez JM, Tchou JC.: Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer. Ann Surg Oncol. 29(3): 1530-1532, March 2022.

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Jelle Wesseling, Martín M, Monte-Millán MD, López-Tarruella S, I-SPY 2 Trial Consortium; Boughey J.C, Goetz M.P, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Mi-Ok K, van 't Veer LG, Esserman LJ, Symmans WF: Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicenter pooled analysis of 5161 patients. Lancet Oncol 23(1): 149-160, Jan 2022.

Clark AS, Yau C, Wolf DM, Petricoin EF, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Albain KS, Tripathy D, Ellis ED, Forero-Torres A, Yung R, Han HS, Lang JE, Viscusi RK, Haley BB, Kemmer K, Elias AD, Nanda R, Boughey JC, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA,Alvarado M, Crane EP, Robinson P, Buxton M, Clennell JL, Paolini M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare AL, Matthews J, Berry S, Snail A, Melissa M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hilton NM, Yee D, Van 't Veer LJ, Berry DA, Esserman LJ, DeMichele AM: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2- positive breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications 12(1): 6428, November 2021 Notes: manuscript under revision.

Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ: Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol September 2021.

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S.: Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clinical Cancer Research August 2021 Notes: doi: 10.1158/1078-0432.CCR-20-2114. Online ahead of print.

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ.: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell 39 : 989-998, July 2021.

Miller KD, Zhao F, Clark AS, Wilkinson G, Heineman T, Wolff A: BRACELET-1 (PrE0113): A Study To Assess Overall Response Rate By Inducing An Inflammatory Phenotype In Metastatic Breast Tumors With The Oncolytic Reovirus Pelareorep In Combination With Anti-PD-L1 Avelumab And Paclitaxel. ASCO Annual Meeting 2021 June 2021 Notes: Poster Presentation submitted for ASCO Annual Meeting 2021.

back to top
Last updated: 05/16/2022
The Trustees of the University of Pennsylvania